U.S. Markets closed

Kura Oncology, Inc. (KURA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
12.59+0.46 (+3.79%)
At close: 04:00PM EDT
12.59 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close12.13
Bid10.10 x 1300
Ask19.63 x 800
Day's Range11.90 - 12.81
52 Week Range10.41 - 24.36
Avg. Volume628,640
Market Cap837.938M
Beta (5Y Monthly)1.39
PE Ratio (TTM)N/A
EPS (TTM)-1.92
Earnings DateFeb 22, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est35.88
  • GlobeNewswire

    Kura Oncology Reports First Quarter 2022 Financial Results

    – Enrollment completed in Phase 1b expansion cohorts for ziftomenib; topline data expected in third quarter, full data presentation in fourth quarter – – Enrollment in PIK3CA-dependent cohort in KURRENT-HN trial of tipifarnib plus alpelisib continues; first patient in HRAS overexpression cohort expected by third quarter – – First patient in Phase 1 KURRENT-LUNG trial of tipifarnib plus osimertinib expected in third quarter – – $480 million in cash, cash equivalents and investments provide runway

  • GlobeNewswire

    Kura Oncology to Report First Quarter 2022 Financial Results

    SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2022 financial results after the close of U.S. financial markets on Wednesday, May 4, 2022. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a c

  • GlobeNewswire

    Kura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer

    – Late-breaking presentation at AACR demonstrates potential to significantly delay onset of drug resistance to EGFR-targeted therapies through combination with a farnesyl transferase inhibitor – – Company to initiate clinical trial of tipifarnib in combination with osimertinib in NSCLC in the third quarter of 2022 – – IND for KO-2806, a next-generation farnesyl transferase inhibitor, remains on track for submission in the fourth quarter of 2022 – SAN DIEGO, April 08, 2022 (GLOBE NEWSWIRE) -- Kur